scholarly journals Ahmed valve implantation results in neovascular glaucoma patients: Evaluation of short-term and remote

2015 ◽  
Vol 8 (3) ◽  
pp. 20-23
Author(s):  
Olga Gennadievna Pavlova ◽  
Vadim Petrovich Nikolaenko
Keyword(s):  
Intraocular Pressure ◽  
Pain Syndrome ◽  
Neovascular Glaucoma ◽  
Anterior Chamber Angle ◽  
Short Term ◽  
Lowering Therapy ◽  
Ahmed Valve ◽  
Valve Implantation ◽  
Implantation Method ◽  
Main Complication

Objective: to evaluate Ahmed valve implantation results in neovascular glaucoma patients. Methods: standard implantation method was used in 87 patients aged 57-86 years. Check-up examinations were performed in 1 week, 1, 3, 6, 9, 12 and 36 months after surgery. Results: during short-term post-op period (one month after surgery), intraocular pressure normalized in 48 patients. During remote post-op period (6-36 months after surgery), intraocular pressure normalization was achieved in 69 patients (79.2 %), among them in 62 patients (71.2 %) - against the background of IOP-lowering treatment. The main complication was a hemorrhage from anterior chamber angle and iris new vessels that was found in 37 patients (42.5 %), in a quarter of cases it required hyphema washout. In three patients, sustained hypotony developed, in one case it brought to globe sub-atrophy. In two of observed patients, enucleation was performed because of pain syndrome rebound. Conclusions: In 79.2 % neovascular glaucoma patients, the valve implantation led to IOP normalization, while in 71.2 % of cases it required a return to IOP-lowering therapy.

scholarly journals Ahmed valve implantation results in children with uveitic glaucoma

2021 ◽  
Vol 14 (1) ◽  
pp. 30-34
Author(s):  
L. A. Katargina ◽  
E. V. Denisova ◽  
I. N. A. Bahaaeddin ◽  
M. A. Khrabrova
Keyword(s):  
Intraocular Pressure ◽  
Surgical Treatment ◽  
Hypotensive Effect ◽  
Open Angle ◽  
Anterior Chamber Angle ◽  
Safe Method ◽  
Ahmed Valve ◽  
Valve Implantation ◽  
Chamber Angle

The purpose is to evaluate the effectiveness and safety of Ahmed valve implantation in children with refractory postuveitic glaucoma (PUG).Material and methods. Ahmed valve was implanted to 10 children aged 7 to 17 years (10 eyes) with open-angle or mixed PUG uncompensated even by a maximum antihypertensive mode. Previously, all patients had undergone an average of 2.1 ± 0.9 surgeries aimed at normalizing the intraocular pressure (IOP) (predominantly, sinus trabeculectomy). 6 eyes were pseudophakic, 2 phakic, 2 aphakic. Ahmed valves were implanted according to the generally accepted technique. At the time of surgery IOP was 30.50 ± 4.35 mm Hg on average. The follow-up postsurgical period ranged from 3.9 to 23.6 months (averagely, 14.1 ± 6.5).Results. A stable hypotensive effect of the intervention was achieved in 90 % of cases, of which 3 patients had no hypotensives while 6 patients received hypotensive drugs even though their quantity was significantly smaller than before surgery (1.7 ± 1.49, p=0.028). At the end of the follow-up the average IOP was 18.1 ± 5.34 mm Hg, (significantly lower than before surgery, p = 0.008). During surgery, 1 patient experienced bleeding from the vessels of the anterior chamber angle after paracentesis, which was stopped by tamponade with sterile air. In other cases, the surgery as well as the immediate and distant postoperative period showed no complications.Conclusion. Ahmed valve implantation is an effective and safe method of the surgical treatment of refractory PUG in children and can be recommended in cases when previous antiglaucomatous operations proved ineffective, including patients with pseudophakia and aphakia.

In Vivo Corneal Endothelial Safety of Intracameral Bevacizumab and Effect in Neovascular Glaucoma Combined With Ahmed Valve Implantation

2009 ◽  
Vol 18 (8) ◽  
pp. 589-594 ◽  
Author(s):  
Jae Pil Shin ◽  
Ji Woong Lee ◽  
Byung Jae Sohn ◽  
Hong Kyun Kim ◽  
Si Yeol Kim
Keyword(s):  
Neovascular Glaucoma ◽  
Ahmed Valve ◽  
Valve Implantation

scholarly journals Safety and Efficacy of Second Ahmed Valve Implant in Refractory Glaucoma

2020 ◽  
Vol 9 (7) ◽  
pp. 2039
Author(s):  
Chiara Posarelli ◽  
Mario Damiano Toro ◽  
Robert Rejdak ◽  
Tomasz Żarnowski ◽  
Dorota Pożarowska ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Demographic Data ◽  
Case Series ◽  
Glaucoma Surgery ◽  
Refractory Glaucoma ◽  
Safety And Efficacy ◽  
Surgical Success ◽  
Ahmed Valve ◽  
Valve Implantation ◽  
Type 3

Background: Refractory glaucoma still represents a challenge for ophthalmologists to manage intraocular pressure. The present study aimed to evaluate long term efficacy and safety of a second Ahmed valve implantation after the failure of a first implant in patients with refractory glaucoma and elevated intraocular pressure (IOP). Methods: Retrospective, multicenter non-comparative case series. Twenty-eight patients were retrospectively recruited between January 2011 and December 2017. Demographic data, glaucoma type, visual acuity, intraocular pressure, medical therapy, and complications were registered. Three criteria of success were established: Type 1 surgical success: IOP ≤ 15 mmHg and a reduction of IOP ≥ 40% from baseline; Type 2 surgical success: IOP ≤ 18 mmHg and a reduction of IOP ≥ 30% from baseline; and Type 3 surgical success: IOP ≤ 21 mmHg and a reduction of IOP ≥ 20% from baseline. Surgical failure has been established as IOP less than 5 mmHg or over 21 mmHg and less than a 20% reduction of IOP from baseline despite medications in two consecutive visits, light perception loss referable to glaucoma, and the necessity for further glaucoma surgery. Failure was observed in six (21%) patients. (3) Results: Mean IOP and mean glaucoma medication number significantly reduced from baseline after the second implantation, and the surgical success rate at 72 months ranged from 10% to 78% based on the different criteria of success. Failure was observed in six (21%) patients. Conclusions: This study confirmed the safety and efficacy of a second Ahmed valve implantation in patients with refractory glaucoma and elevated IOP at baseline.

Surgical Results of Ahmed Valve Implantation With Intraoperative Bevacizumab Injection in Patients With Neovascular Glaucoma

2012 ◽  
Vol 21 (5) ◽  
pp. 331-336 ◽  
Author(s):  
Kyoung Tak Ma ◽  
Jong Yun Yang ◽  
Ji Hyun Kim ◽  
Na Rae Kim ◽  
Samin Hong ◽  
...  
Keyword(s):  
Neovascular Glaucoma ◽  
Surgical Results ◽  
Ahmed Valve ◽  
Valve Implantation ◽  
Bevacizumab Injection

scholarly journals Ahmed valve implantation: intraoperative and early postoperative complications

2014 ◽  
Vol 7 (4) ◽  
pp. 10-12 ◽  
Author(s):  
Vadim Petrovich Nikolaenko ◽  
Larisa Mikhaylovna Kontantinova ◽  
Ol'ga Gennad'yevna Pavlova
Keyword(s):  
Postoperative Complications ◽  
Surgical Technique ◽  
Scar Tissue ◽  
Corneal Perforation ◽  
Anterior Chamber Angle ◽  
Early Postoperative Complications ◽  
Ahmed Valve ◽  
Preparatory Stage ◽  
Valve Implantation ◽  
Choroidal Effusion

Purpose. To analyze the causes of intraoperative and early postoperative complications and to develop a plan to improve the surgical technique. Methods. An Ahmed valve implantation by a standard method with obligatory posterior sclerectomy was performed in 238 patients aged from 18 to 88 years. Results. There were 7 cases of corneal perforation during the preparatory stage in excessively deep bridle suture; 3 cases of conjunctival and scleral perforation; 4 cases of inadvertent orifice enlargement in needle perforation of limbal scar tissue with consequent excessive filtration; in 37 patients, there was a hemorrhage from new vessels situated in the anterior chamber angle and the iris; 59 cases of serous cilio-choroidal effusion; 12 cases of hemorrhagic detachment. Conclusions. It is mandatory to follow the main principles of surgical technique and to take into consideration associated diseases.

scholarly journals INTRAVITREAL INTRODUCTION OF LUCENTIS AND TRANS-SCLERAL CYCLOPHOTOCOAGULATION IN THE TREATMENT OF NEOVASCULAR GLAUCOMA IN DIABETES MELLITUS

2016 ◽  
Vol 1 (6) ◽  
pp. 122-124
Author(s):  
Ефремова ◽  
Tatyana Efremova ◽  
Балалин ◽  
Sergey Balalin ◽  
Фокин ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Intraocular Pressure ◽  
Anterior Chamber ◽  
Laser Surgery ◽  
Neovascular Glaucoma ◽  
Mean Value ◽  
Anterior Chamber Angle ◽  
Second Stage ◽  
Anti Vegf ◽  
Chamber Angle

We analyzed the results of surgical treatment of 42patients (42eyes) with neovascular glaucoma on the background of proliferative diabetic retinopathy. Intravitreal injections of anti-VEGF-drugs allow to remove newly formed vessels in anterior chamber angle, to reduce intraocular pressure, to avoid complications in patients with neovascular glaucoma and the closed anterior chamber angle of the eye. The second stage of the treatment can be laser surgery. This approach helped to reduce intraocular pressure from 28.9±0.9 to 18.5±0.9mmHg on the background of medical treatment (t>2.0; p<0.05). Visual acuity increased from 0.23±0.07 to 0.44±0.08 (t>2.0; p<0.05).In patients with NVG and closed anterior chamber angle of the eye, having aching glaucoma the use of laser surgery as the first stage of treatment allows to reduce intraocular pressure and to eliminate pain, and to apply intravitreal anti-VEGF-therapy as the second stage. The mean value of IOP decreased from 30.9±1.2 to 20.1±1.1mmHg. During the year period, the second stage (intravitreal introduction of Lucentis) was performed in all patients. As a result, IOP was reduced to 17.5±0.09mmHg. Visual acuity increased from 0.18±0.1 to 0.25±0.07 (p>0.05).

scholarly journals Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy

2016 ◽  
Vol 2016 ◽  
pp. 1-7
Author(s):  
Xi Shen ◽  
Yanwei Chen ◽  
Yanuo Wang ◽  
Lu Yang ◽  
Yisheng Zhong
Keyword(s):  
Adjuvant Therapy ◽  
Case Series ◽  
Vitreous Hemorrhage ◽  
Neovascular Glaucoma ◽  
Vitreous Surgery ◽  
Intravitreal Ranibizumab ◽  
Additional Surgery ◽  
Ahmed Valve ◽  
Valve Implantation

Purpose.To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of neovascular glaucoma (NVG) accompanied by postvitrectomy diabetic vitreous hemorrhage (PDVH).Methods.Eighteen NVG patients (18 eyes) accompanied by PDVH were enrolled in this prospective, monocenter, 12-month, interventional case series. The consecutive 18 patients with an IOP ≥ 25 mmHg despite being treated with the maximum medical therapy were treated with intravitreal ranibizumab injections. Vitreous surgery or/with Ahmed valve implantation were indicated if no clinical improvement in vitreous haemorrhage and uncontrolled IOP was shown.Results.Ten patients got clear vitreous and controlled IOP only with2.7±1.8injections of ranibizumab without additional surgery. Vitrectomy or/with Ahmed valve implantation was administered in the other 8 eyes due to uncontrolled VH and IOP. At follow-up month 12, all the 18 eyes gained clear vitreous. At month 12 BCVA improved significantly compared to baseline. The baseline and follow-up at month 12 IOP/medication usage were36.7±8.1 mmHg on3.4±0.7medications and16.2±4.9 mmHg on0.67±0.77medications, respectively.Conclusions.The findings suggest that intravitreal ranibizumab injection as adjuvant therapy for treatment of NVG accompanied by PDVH may be safe and potentially effective. This clinical trial is registered withNCT02647515.

Sign in / Sign up

Export Citation Format

Share Document